GlassScriptPhysician profile
Qi Zhi
NPI 1003683194
$5,372.44
in general payments reported to CMS, 2019-2025
29 companies · $4,316 in 2025
The $4,316 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,057 · 2025: $4,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,534 · Travel and Lodging: $1,838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,534.10 |
| Travel and Lodging | $1,838.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $2,197.46 | 2025 | Vns Therapy |
| Alexion Pharmaceuticals, INC. | $711.50 | 2024-2025 | Ultomiris, Soliris |
| Argenx US, INC. | $436.27 | 2024-2025 | Vyvgart Hytrulo |
| Eisai INC. | $361.24 | 2024-2025 | |
| Abbvie INC. | $234.41 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $187.08 | 2024-2025 | |
| Tg Therapeutics, INC. | $156.49 | 2025 | |
| Amgen INC. | $119.92 | 2025 | |
| Sk Life Science, INC. | $117.21 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $92.48 | 2024 | Gammagard, Hyqvia |
| Ucb, INC. | $87.08 | 2025 | Fintepla, Rystiggo |
| Lundbeck LLC | $80.92 | 2024-2025 | Vyepti |
| Vanda Pharmaceuticals INC. | $57.33 | 2025 | Ponvory |
| Tanabe Pharma America, INC. | $45.66 | 2025 | Radicava |
| Novartis Pharmaceuticals Corporation | $45.45 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catalyst Pharmaceuticals, INC. | $44.69 | 2025 | |
| Neurelis, INC. | $43.29 | 2025 | Valtoco |
| Acadia Pharmaceuticals INC | $42.01 | 2025 | Nuplazid, Daybue |
| Genentech USA, INC. | $40.50 | 2024-2025 | Ocrevus, Ocrevus Zunovo |
| Teva Pharmaceuticals USA, INC. | $40.47 | 2024 | Ajovy, Austedo Xr |
| Ipsen Biopharmaceuticals, INC | $33.69 | 2024 | Dysport |
| Avadel Cns Pharmaceuticals, LLC | $30.35 | 2024 | Lumryz |
| Amneal Pharmaceuticals LLC | $27.67 | 2025 | Crexont |
| Mallinckrodt Hospital Products INC. | $27.61 | 2025 | Acthar |
| Janssen Biotech, INC. | $26.27 | 2025 | |
| Cycle Pharmaceuticals INC | $24.02 | 2025 | Bafiertam |
| Cala Health, INC. | $21.39 | 2024 | Cala Trio, Cala Kiq |
| Inspire Medical Systems, INC. | $20.74 | 2025 | Inspire |
| Emd Serono, INC. | $19.24 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Qi Zhi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.